<DOC>
	<DOCNO>NCT02378883</DOCNO>
	<brief_summary>The purpose study evaluate safety Apollo™ Onyx™ Delivery Micro Catheter use delivery Onyx™ Liquid Embolic System brain arteriovenous malformation ( AVM ) embolization procedure .</brief_summary>
	<brief_title>Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<criteria>The Subject Subject 's legally authorize representative sign date informed consent form . The Subject confirm diagnosis brain AVM . The Subject clinically neurologically stable minimum 48 hour prior embolization . The Subject life expectancy least 1 year . The Subject agree capable complete studyrequired procedure . Current participation another investigational drug device study evaluate treatment brain AVMs cerebrovascular disease . The Subject bleeding disorder . The Subject candidate use vasodilator .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Apollo</keyword>
	<keyword>Onyx</keyword>
	<keyword>arteriovenous malformation</keyword>
	<keyword>AVM</keyword>
	<keyword>Onyx™ Liquid Embolic System</keyword>
	<keyword>Apollo™ Onyx™ Delivery Micro Catheter</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>